NCT01979614View on ClinicalTrials.gov

Study of the Vascular Effects of Serelaxin

PHASE2CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

February 3, 2014

Primary Completion Date

August 17, 2016

Study Completion Date

August 17, 2016

Conditions
Coronary Artery Disease
Interventions
DRUG

Serelaxin

Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution

OTHER

Placebo

5% v/v glucose solution

Trial Locations (3)

G81 4HX

Novartis Investigative Site, Clydebank

EHN 2XU

Novartis Investigative Site, Edinburgh

LE3 9QP

Novartis Investigative Site, Leicester

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY